Mohamed Elsafy։ Rethinking Hemostatic Management in Glanzmann Thrombasthenia with Sutacimig
Mohamed Elsafy, Drug Safety and Pharmacovigilance Lead Physician, Global Safety Strategy and Governance at ClinRM LLC, shared a post on LinkedIn:
”Sutacimig represents a novel and potentially transformative approach in Glanzmann thrombasthenia, shifting the paradigm from reactive bleeding management to true prophylaxis.
By leveraging a bispecific mechanism to localize and stabilize endogenous Factor VIIa at the platelet surface, this strategy directly addresses the underlying hemostatic defect. Early data showing meaningful reductions in bleeding burden are encouraging, particularly in a setting with no established preventive options.
If sustained in later-stage studies, this could redefine the standard of care in rare platelet disorders.”
Stay updated with Hemostasis Today.
-
Nov 18, 2026, 20:58Uma Vaidyanathan: When Hemoglobin Does Not Respond to Iron Therapy, Look Beyond Iron Deficiency
-
Nov 18, 2026, 20:57Jamil Rafiq: 5 Ways to Prevent Sample Haemolysis
-
Nov 18, 2026, 20:55Nasir Jamal: Plasmapheresis – Key Concepts at a Glance
-
Nov 18, 2026, 20:55Tarık Seller: Pulmonary Embolism – When a Blood Clot Becomes a Life-Threatening Emergency
-
Nov 18, 2026, 20:53Sandya Arunachalam: Bringing the Profession Together at the Haemostasis and Thrombosis Workshop
-
Nov 18, 2026, 15:11Vansh Yaduvanshi: Why Compatible Blood Groups Do Not Always Mean Compatible Blood
-
Nov 18, 2026, 14:49Estetrol-Based Contraception in PCOS and Its Effects on Coagulation – RPTH Journal
-
Nov 18, 2026, 14:41Factor V Deficiency: Diagnostic Challenges and the Role of Combined Factor V and VIII Deficiency
-
Nov 18, 2026, 14:29Maxime Dely: When Patient Encounters Become Life Lessons